BioAtla IPO Presentation Deck
Summary and Conclusions
BioAtla is well positioned to develop a strong franchise of CAB-enabled treatments
ID
肿
Innovative CAB technology platform, with clinically-validated antibodies, that conditionally
activate at optimal exposure levels, exhibit high potency, and possess ideal safety profiles
Multiple clinical assets demonstrating differentiated CAB technology and strong results
for challenging targets, leading to novel therapeutics that can fulfill previously unmet
patient needs, and resulting in a broad and diverse pipeline
Strong intellectual property foundation that provides worldwide coverage and multiple
diversified patents for each product
bicatla
Talented and experienced management team, with a strong track record and over 20 years
of experience on average with leading biopharmaceutical companies
Strong financial support through a global collaboration with BeiGene and backing of
reputable investors such as Pfizer Ventures, Soleus Capital, and HBM Healthcare
Investments
30View entire presentation